Yesterday, Regulus Therapeutics Inc (NASDAQ:RGLS) disclosed unpleasant updates regarding the company’s pipeline. The drug maker announced three program discontinuations, which include drugs: RG-101, a …
Analysts are weighing in on Ophthotech Corp (NASDAQ:OPHT) and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), as shares of both healthcare firms fell sharply today, hitting new …
In a research report released Friday, Chardan analyst Madhu Kumar upgraded shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to a Neutral rating, without providing a price …
In a research report released Thursday, Chardan Capital analyst Gbola Amusa reiterated a Neutral rating on shares of Esperion Therapeutics Inc (NASDAQ:ESPR), with a …
In a research note published Tuesday, Chardan analyst Keay Nakae reiterated a Buy rating on shares of Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) with a price target …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares are up nearly 6% as of this writing, after the RNAi therapeutics company announced a collaboration with Amgen (NASDAQ:AMGN) …
Chardan Capital analyst Keay Nakae is out today with a research note on shares of Novavax, Inc. (NASDAQ:NVAX), reiterating a Neutral rating, while slashing the price …
In a research report released Friday, Chardan Capital analyst Keay Nakae reiterated a Buy rating on shares of Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) with a …
This morning, Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced the initiation of its Phase II trial for its pipeline drug ARC-AAT, a RNAi based investigational …
Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) tumbled 11% today, following the news that the company had received written communication from the FDA requesting additional safety analyses …
